Collaborative Drug Discovery (CDD) is a software company founded in 2004 as a spin-out of Eli Lilly by Barry Bunin, PhD. CDD utilizes a web-based database solution for managing drug discovery data, primarily through the CDD Vault product which is focused around small molecules and associated bio-assay data. In 2021, CDD launched its first commercial data offering, PharmaKB,[1] formerly BioHarmony,[2][3] as The Pharma KnowledgeBase, which is centered around pharma company, drug, and disease information for research, business intelligence, and investors.
Products
1. CDD Vault[4][5] is a research informatics web platform by Collaborative Drug Discovery. It contains several modules for collaborative project teams to manage, analyze, and share both private & public data. It is used by biotech companies, CROs, academic labs, research hospitals, agrochemical and consumer goods companies. CDD Vault is a modern web application for chemical registration, assay data management, and SAR analysis. It is designed to be simple to use and extremely secure.
Web application within CDD Vault for Assay Informatics to allow for easy registration, search, and systematic comparison of assays using standardized protocols and runtime details.
Web application within CDD Vault for Artificial Intelligence (AI) capabilities such as identifying similar compounds, synthesizable molecules, bioisosteric suggestions, and patent issues.
Free database also integrated within CDD Vault for fostering open collaboration containing over 3 million molecules accessible to everyone in the drug discovery community.
2. PharmaKB is a knowledgebase for pharma-related information. Available data spans (preclinical, clinical, financial, patents, and post-approval) information about companies, drugs, and diseases. It is designed to be used by researchers, those practicing business intelligence, and investors. PharmaKB also offers real-time updates with a subscription model instead of static reports. As a throwback to CDD Vault's slogan of "Complexity Simplified", PharmaKB uses the slogan of "Data Simplified" and promotes a data trilogy of Company, Drug, and Disease. The product is meant to expand the company's scope from working with mostly preclinical researchers to being relevant for clinical and post-approval stages of drug development, including: Pharmacovigilance or Drug Safety, Regulatory Affairs, Competitive Intelligence - also referred to as Pharma Intelligence within its industry, and Pharmacoeconomics as well as investors and publishers of medical content.
Collaborations
The capability for inter-group collaboration attracted attention from the Bill & Melinda Gates Foundation, who in 2008 awarded CDD with a two million dollar grant being used to support researchers combating tuberculosis.[16]
In February 2011 CDD began participating in the collaborative MM4TB project led by Stewart Cole[21] and including participants from AstraZeneca and Sanofi Aventis.[22]
^Ekins S and Williams AJ, Meta-analysis of molecular property patterns and filtering of public datasets of antimalarial “hits” and drugs, MedChemComm, 1: 325-330, 2010. doi:10.1039/C0MD00129E
^Ekins S, Kaneko T, Lipinski CA, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Ernst S, Yang J, Goncharoff N, Hohman M and Bunin BA, Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis, Mol Biosyst, 6: 2316-2324, 2010, doi:10.1039/C0MB00104J